Mustang Bio Inc
MBIO
Company Profile
Business description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Contact
95 Sawyer Road
Suite 110
WalthamMA02453
USAT: +1 781 652-4500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
4
Stocks News & Analysis
stocks
Chart of the Week: What 650 IPOs reveal about long-term performance
Our data shows buying into the IPO hype can be costly.
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.60 | 54.00 | -0.60% |
| CAC 40 | 8,431.61 | 46.12 | 0.55% |
| DAX 40 | 25,000.54 | 260.18 | 1.05% |
| Dow JONES (US) | 52,242.05 | 393.15 | 0.76% |
| FTSE 100 | 10,529.89 | 68.26 | 0.65% |
| HKSE | 23,076.91 | 335.27 | -1.43% |
| NASDAQ | 25,380.51 | 96.13 | -0.38% |
| Nikkei 225 | 72,366.34 | 3,191.38 | 4.61% |
| NZX 50 Index | 13,493.05 | 92.39 | 0.69% |
| S&P 500 | 7,372.87 | 14.65 | 0.20% |
| S&P/ASX 200 | 8,748.70 | 51.90 | -0.59% |
| SSE Composite Index | 4,120.28 | 9.47 | 0.23% |